Rondaxe Pharma, LLC

Website Links

Description

Hugh Delargy is an experienced Regulatory Affairs consultant and has been working with Rondaxe since 2012. After originally working as a pharmacist, Hugh joined E.R. Squibb and later ConvaTec where he had responsibility for analytical method development, quality control for clinical trial material, and formulation stability testing and development.

Dr. Levy began working with Rondaxe in 2011. Stuart has sixteen years of industrial experience in all aspects of chemical development. He has extensive experience in innovation in the conception of practical synthetic routes to pharmaceuticals, development of chemical processes for the manufacture of APIs and chemical process troubleshooting. He is a hands-on, results-oriented leader of multidisciplinary teams focused on process discovery, process development, scale-up and cGMP kilo lab production.

Rondaxe is dedicated to providing strategically and scientifically sound solutions to our customers. Our proven track record of delivering results ensures rapid, risk-reduced and cost efficient progression of clinical candidates through development and commercialization processes. Our success and growth is driven by our seasoned scientific team, and industry leading technology. We place the utmost importance on providing the necessary expertise and resources towards our customers’ success.

Chris Williamson began working with Rondaxe in 2010. Chris has over 35 years of experience in drug discovery, development and sourcing with GlaxoSmithKline. Chris began his career as a research chemist with Glaxo before moving into chemical development roles including commissioning and validation of commercial processes. For over ten years, Chris was the Technical Director responsible for outsourcing, third party contract manufacturing, and technology transfer for the API supply division in GSK while based at the Dartford facility.

Ms. Meissner began working with Rondaxe in 2012. She has more than 15 years’ experience in downstream processing for mammalian cell and recombinant products, liposomal formulation, and artificial internal organs based on encapsulation of cells for implants. Dagmar started her career at Biogen in process development, working in virtually all areas of downstream purification and isolation. She went on to work with DepoTech on developing formulations and processes for sustained release formulations.

Companies nearby